• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath's Chemosat gives terminal cancer patients several more months of disease-free life

September 26, 2011 By drugdelivery

Delcath Chemosat

Delcath Systems Inc.’s (NSDQ:DCTH) Chemosat organ-targeting chemotherapy system extended the lives of terminal eye cancer patients by several months without disease progression, researchers said.

Melanoma of the eye often spreads to the liver, generally killing a patient in 1 to 2 months, according to a press release. Patients who received targeted treatment to saturate the liver lived an average of 8.1 months, compared to 1.6 months for patients receiving the best alternative care.

"This is the first treatment to show a clinical benefit in patients with liver metastases from ocular melanoma," Dr. Jampes Pingpank, who presented the data at the European CanCer Organization meeting in Stockholm, Sweden, said in prepared remarks. "Most patients retain 80% or more of their daily functional status, and return to full performance once therapy is completed."

Check out our interview with Delcath president & CEO Eamonn Hobbs.

The Chemosat device uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ — in this case, the liver — from the rest of the body’s bloodstream.

Isolating the drug allows physicians to use doses several times higher than current standards, and allows physicians to follow up a focused dose of chemo to the liver with a systemic dose to target cancerous tissue throughout the body.

The Phase III randomized trial took place in nine U.S. clinics including 93 patients. As the benefit of Chemosat therapy become more apparent, patients were allowed to cross over from the control arm to get the experimental treatment.

Chemosat won CE Mark approval in the European Union for treatment of liver cancer in April, Hobbs told MassDevice in June, but the device has suffered some regulatory hiccups on the way to FDA clearance.

Filed Under: Drug-Device Combinations, Research & Development Tagged With: Clinical Trials, Delcath Systems Inc.

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS